College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China.
ACS Biomater Sci Eng. 2020 May 11;6(5):3217-3229. doi: 10.1021/acsbiomaterials.0c00286. Epub 2020 Apr 15.
High invasion and metastasis are the major obstacles to successful breast cancertherapy. Indocyanine green (ICG), a photosensitizer for photothermal therapy (PTT), shows potent anticancer efficacy when combined with the chemotherapeutic drug doxorubicin (DOX). Human serum albumin (HSA), a biocompatible carrier material, has been successfully used for the delivery of paclitaxel (Abraxane). In addition, there are ICG functional binding regions in HSA. Thus, a smart assembled nanoplatform (DI@HSA NPs) was constructed to achieve the synergistic effects of chemo- photothermal therapy against breast cancer. Compared to free ICG and free DOX, DI@HSA NPs showed satisfactory stability and exhibited an enhanced tumor targeting capacity. The mild hyperthermia generated by DI@HSA NPs can not only cause tumor photothermal ablation and promote the uptake of DI@HSA NPs by 4T1 cells, but also protect the healthy tissues nearby the tumor from overheating injury. More importantly, DI@HSA NPs greatly amplified the infiltration of CD4 T cells and CD8 T cells, resulting in inhibited tumor growth and metastasis. DI@HSA NPs, as a simple biocompatible nanoagent, showed excellent inhibition of breast cancer growth and metastasis by chemo-photothermal therapy, providing a potential strategy for the future therapy of breast cancer.
高侵袭和转移是乳腺癌成功治疗的主要障碍。吲哚菁绿(ICG)作为光热疗法(PTT)的光敏剂,与化疗药物阿霉素(DOX)联合使用时显示出强大的抗癌功效。人血清白蛋白(HSA)作为一种生物相容性载体材料,已成功用于紫杉醇(Abraxane)的递送。此外,HSA 中存在 ICG 的功能结合区域。因此,构建了一种智能组装纳米平台(DI@HSA NPs),以实现化疗-光热联合治疗乳腺癌的协同作用。与游离 ICG 和游离 DOX 相比,DI@HSA NPs 表现出令人满意的稳定性,并表现出增强的肿瘤靶向能力。DI@HSA NPs 产生的温和热疗不仅可以引起肿瘤光热消融并促进 DI@HSA NPs 被 4T1 细胞摄取,还可以保护肿瘤附近的健康组织免受过热损伤。更重要的是,DI@HSA NPs 大大增强了 CD4 T 细胞和 CD8 T 细胞的浸润,从而抑制了肿瘤的生长和转移。DI@HSA NPs 作为一种简单的生物相容性纳米制剂,通过化疗-光热疗法显示出对乳腺癌生长和转移的优异抑制作用,为乳腺癌的未来治疗提供了一种潜在策略。